Product Description
Aldesleukin is used to treat advanced renal cell carcinoma (RCC, a type of cancer that begins in the kidney) that has spread to other parts of your body. Aldesleukin is also used to treat melanoma (a type of skin cancer) that has spread to other parts of your body. Aldesleukin is in a class of drugs known as cytokines. It is a man-made version of a naturally occurring protein that stimulates the body to produce other chemicals which increase the body's ability to fight cancer. (Sourced from: https://medlineplus.gov/druginfo/meds/a692009.html)
Mechanisms of Action: IL2 Inhibitor
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Intravenous, Subcutaneous
FDA Designation: *
Approval Status: Approved
Approved Countries: Austria | Belgium | Brazil | Canada | Chile | Colombia | Dominican Republic | France | Germany | Greece | Hungary | Ireland | Italy | Korea | Netherlands | New Zealand | Peru | Portugal | Slovenia | Spain | Switzerland | Taiwan | Turkey | United Kingdom | United States | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Chiron
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China, France, Germany, Hong Kong, Israel, Korea, New Zealand, United Kingdom, United States
Active Clinical Trial Count: 19
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Adenocarcinoma|Alzheimer Disease|Anal Cancer|Anus Cancer|Bladder Cancer|Carcinoma, Adenosquamous|Carcinoma, Merkel Cell|Cervical Cancer|Colorectal Cancer|Cutaneous Squamous Cell Carcinoma|Diabetes Complications|Digestive System Cancer|Esophageal Cancer|Gallbladder Cancer|Gastrointestinal Cancer|Head and Neck Cancer|Melanoma|Neuroblastoma|Non-Small-Cell Lung Cancer|Oropharyngeal Cancer|Ovarian Cancer|Pancreatic Cancer|Penile Cancer|Prostate Cancer|Renal Cell Carcinoma|Skin Cancer|Soft Tissue Cancer|Squamous Cell Carcinoma|Synovial Sarcoma|Transitional Cell Carcinoma|Triple Negative Breast Cancer|Type 1 Diabetes|Uterine Cancer|Vaginal Cancer|Vulvar Cancer
Phase 1: Breast Cancer|Hepatitis B|Lung Cancer|Mesothelioma|Oncology Solid Tumor Unspecified|Pleural Effusion, Malignant
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07192900 |
(RIOT 4A) | P1 |
Not yet recruiting |
Mesothelioma|Pleural Effusion, Malignant |
2032-10-01 |
12% |
2025-09-26 |
Primary Endpoints|Treatments |
NCT05483491 |
Pro2022002198 | P1 |
Recruiting |
Breast Cancer|Gastrointestinal Cancer|Lung Cancer|Uterine Cancer|Cervical Cancer |
2026-09-01 |
50% |
2024-07-13 |
|
NCT04862767 |
ATB-301-001 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2023-08-21 |
2% |
2024-02-01 |
|
2020-003629-45 |
Study of LN 145 in patients with Metastatic Non-Small-Cell Lung Cancer | P2 |
Active, not recruiting |
Non-Small-Cell Lung Cancer |
2026-05-05 |
12% |
2022-03-13 |
Treatments |
NCT05153070 |
DF-IL2-REP | P2 |
Recruiting |
Type 1 Diabetes |
2026-04-21 |
12% |
2024-11-22 |
|
NCT04426669 |
2019LS002 | P2 |
Active, not recruiting |
Digestive System Cancer|Colorectal Cancer|Pancreatic Cancer|Gastrointestinal Cancer|Esophageal Cancer|Gallbladder Cancer |
2026-01-01 |
12% |
2025-01-18 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT05468073 |
IL-2-AD | P2 |
Recruiting |
Alzheimer Disease |
2025-09-01 |
2024-06-28 |
Primary Endpoints |
|
2012-001786-32 |
IL2HD | P2 |
Completed |
Renal Cell Carcinoma|Melanoma |
2024-12-31 |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
NCT03782636 |
ITAD | P2 |
Active, not recruiting |
Diabetes Complications|Type 1 Diabetes |
2023-02-16 |
2025-10-04 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT07288073 |
NCT07288073 | P2 |
Not yet recruiting |
Carcinoma, Merkel Cell|Cutaneous Squamous Cell Carcinoma|Squamous Cell Carcinoma|Skin Cancer |
2028-09-29 |
12% |
2025-12-18 |
Primary Endpoints|Treatments |
NCT05296564 |
0752-20-HMO | P2 |
Recruiting |
Non-Small-Cell Lung Cancer|Melanoma|Ovarian Cancer|Soft Tissue Cancer|Triple Negative Breast Cancer|Bladder Cancer|Neuroblastoma|Transitional Cell Carcinoma|Synovial Sarcoma |
2027-12-30 |
2023-09-26 |
Primary Endpoints|Treatments |
|
NCT07255664 |
ProbeTILity | P2 |
Recruiting |
Prostate Cancer|Colorectal Cancer |
2027-04-01 |
12% |
2025-12-11 |
Primary Endpoints|Start Date|Treatments|Trial Status |
NCT05639972 |
Pro2022000437 | P2 |
Recruiting |
Penile Cancer|Anus Cancer|Adenocarcinoma|Cervical Cancer|Oropharyngeal Cancer|Anal Cancer|Vulvar Cancer|Squamous Cell Carcinoma|Head and Neck Cancer|Vaginal Cancer|Carcinoma, Adenosquamous|Uterine Cancer |
2026-10-01 |
12% |
2025-04-01 |
Primary Endpoints|Start Date|Treatments|Trial Status |
ACTRN12618001843246p |
2006-7041-83/hah | P1 |
Not yet recruiting |
Hepatitis B |
None |
|||
CTR20231525 |
CTR20231525 | P1 |
Active, not recruiting |
Oncology Solid Tumor Unspecified |
None |
2025-04-29 |
||
2012-001410-41 |
ABSIDE | P2 |
Completed |
Melanoma |
2024-06-20 |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
2020-005068-70 |
DFIL2-REP | P2 |
Active, not recruiting |
Unknown |
2022-12-07 |
2022-03-13 |
Treatments |
|
2025-521227-70-00 |
ProbeTILity | P2 |
Not yet recruiting |
Prostate Cancer|Colorectal Cancer |
2029-03-01 |
12% |
||
NCT05686226 |
Pro2022002259 | P2 |
Recruiting |
Vulvar Cancer|Penile Cancer|Head and Neck Cancer|Colorectal Cancer|Vaginal Cancer|Carcinoma, Adenosquamous|Cervical Cancer|Squamous Cell Carcinoma|Anal Cancer|Adenocarcinoma|Uterine Cancer|Anus Cancer|Oropharyngeal Cancer |
2027-01-01 |
12% |
2025-04-01 |
Primary Completion Date|Primary Endpoints |